background

Our history

Founded in 1996, Royalty Pharma has become the industry leader in investing in marketed and late stage biopharmaceutical products.

Central to our investment strategy is acquiring economic interests in leading pharmaceutical and biotechnology products, and holding these interests for the long term as part of a diversified portfolio. We invest broadly across product and therapeutic classes to capture the fundamentally attractive business model of the pharmaceutical industry, while limiting exposure to the concentrated product risk typical to many biopharmaceutical companies.

The ability to provide competitive capital for highly innovative development-stage products across therapeutic areas, for companies of all sizes, makes Royalty Pharma the leading R&D partner for the biopharmaceutical industry.